ClinicalTrials.gg
Not yet recruitingNCT06644404DW_DWP16001112Updated Oct 16, 2024

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

A Phase 1 interventional study of DWP16001 0.3mg and DWC202407 1,000mg in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults

Read the detailed description

This study aims to evaluate the pharmacokinetic interactions, pharmacodynamic interactions, safety, and tolerability of DWP16001, DWC202407, and DWC202408 in healthy adults

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Healthy adult volunteers aged 19 to 50 years at the time of screening.
  2. Individuals with a body weight between 50.0 kg and 90.0 kg and a (BMI) between 18.5 kg/m² and 29.9 kg/m² at the time of screening.
  3. Female volunteers must be neither pregnant nor breastfeeding, or must be in a surgically sterile state (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
  4. Individuals who have been fully informed about the clinical trial, have fully understood the details, voluntarily decided to participate, and provided written consent to comply with the precautions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin 0.3mg, once daily

    Drug: DWP16001 0.3mg

  • Experimental
    Metformin 1,000mg, BID

    Drug: DWC202407 1,000mg

  • Experimental
    Glimepiride 2mg, once daily

    Drug: DWC202408 2mg

Interventions

  • 1 tablet, Orally, Once daily single dose

  • DrugDWC202407 1,000mg

    1 tablet, Orally, Twice daily

  • DrugDWC202408 2mg

    1 tablet, Orally, Once daily single dose

06

What researchers measure

Primary outcomes

  1. Cmax,ss of DWP16001

    Peak Plasma Concentration at steady-state

    Time frame: 0-24 hours

  2. AUCtau,ss of DWP16001

    Area under the plasma concentration versus time curve at Tau, steady-state

    Time frame: 0-24 hours

  3. Cmax,ss of DWC202407

    Peak Plasma Concentration at steady-state

    Time frame: 0-12 hours

  4. AUCtau,ss of DWC202407

    Area under the plasma concentration versus time curve at Tau, steady-state

    Time frame: 0-12 hours

  5. Cmax,ss of DWC202408

    Peak Plasma Concentration at steady-state

    Time frame: 0-24 hours

  6. AUCtau,ss of DWC202408

    Area under the plasma concentration versus time curve at Tau, steady-state

    Time frame: 0-24 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Dec 2024, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 16, 2024
StartEst.
Oct 26, 2024
Primary completionEst.
Dec 3, 2024
CompletionEst.
Apr 1, 2025
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644404
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 26, 2024 (estimated)
Primary completion
Dec 3, 2024 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Oct 16, 2024

Study contacts

DaYe Jung
Contact
dayejung@daewoong.co.kr
+82-2-550-8317

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion